« Back
Home /
BTX-A51

BTX-A51

Item no.	HY-123954-5mg
Manufacturer	MedChem Express
CASRN	2079068-74-7
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.58
Formula	C18H25ClN6
Citations	[1]Waleed Minzel, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.
Smiles	N[C@H]1CC[C@H](NC2=NC=C(Cl)C(C3=C(CC4CC4)N(C)N=C3)=N2)CC1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Casein Kinase inhibitor A51
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Casein Kinase; CDK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	360.88
Product Description	BTX-A51 (Casein Kinase inhibitor A51) is a potent and orally active casein kinase 1α (CK1α) inhibitor. BTX-A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Stem Cell/Wnt
Isoform	CDK7; CDK9; CK1
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Request delivery time